Analystreport

Clementia Pharmaceuticals (NASDAQ: CMTA) is now covered by analysts at B. Riley. They set a "buy" rating and a $25.00 price target on the stock.

CLEMENTIA PHARMACEUTICALS INC COMMON SHARES  (CMTA) 
Last clementia pharmaceuticals inc common shares earnings: 11/7 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.clementiapharma.com/investor-relations